BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.50M | 24.62M | 21.63M | 9.27M | 7.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.86M | 145.82M | 124.29M | 94.77M | 88.55M |
| Operating Income | -168.86M | -145.82M | -124.29M | -94.77M | -88.55M |
| Income Before Tax | -154.10M | -134.04M | -114.93M | -87.50M | -80.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -154.10 | -134.04 | -114.93 | -87.50 | -80.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -154.10M | -134.04M | -114.93M | -87.50M | -80.89M |
| EBIT | -168.86M | -145.82M | -124.29M | -94.77M | -88.55M |
| EBITDA | -168.56M | -145.54M | -124.04M | -94.55M | -88.34M |
| EPS Basic | -52.40 | -106.10 | -1.18K | -2.74K | -2.86K |
| Normalized Basic EPS | -32.75 | -66.31 | -736.73 | -1.71K | -1.79K |
| EPS Diluted | -52.40 | -106.10 | -1.18K | -2.74K | -2.86K |
| Normalized Diluted EPS | -32.75 | -66.31 | -736.73 | -1.71K | -1.79K |
| Average Basic Shares Outstanding | 204.08M | 124.45M | 44.48M | 1.00M | 560.80K |
| Average Diluted Shares Outstanding | 204.08M | 124.45M | 44.48M | 1.00M | 560.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |